ELVN on Nasdaq

Enliven Therapeutics, Inc.

American pharmaceutical preparations company based in Boulder.

Price unavailable

Last updated Oct 18, 2026.

Overview

Compare with another stock.

TickerELVN on Nasdaq
IndustryPharmaceutical Preparations
HeadquartersDE
Incorporated inDE²
Business address205 Park Road, Burlingame, Ca 94010²
Filer categoryNon-accelerated filer²

See how the biggest companies compare on our leaderboards

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Financial statements

Operating income³⁴⁵⁶⁷⁸-$119.7M in 2025+396% since 2019

Net income³⁴⁵⁶⁷⁸-$103.7M in 2025+342% since 2019

Every line of the income statement as filed: the last 2 fiscal years, latest first.⁸

Period ending	2025-12-31	2024-12-31
Research and development	$85.9M	$80.8M
General and administrative	$33.8M	$23.8M
Total operating expenses	$119.7M	$104.6M
Loss from operations	-$119.7M	-$104.6M
Interest income	$16.0M	$14.9M
Change in fair value of contingent value right liability	$0	$873.0K
Income tax expense	$0	-$232.0K
Other expense	-$49.0K	-$2.0K
Total other income (expense), net	$16.0M	$15.5M
Net loss	-$103.7M	-$89.0M
Net unrealized gains (losses) on marketable securities	$279.0K	-$86.0K
Comprehensive loss	-$103.4M	-$89.1M
Net loss per share, basic	-$1.83	-$1.89
Net loss per share, diluted	-$1.83	-$1.89
Weighted-average shares outstanding, basic	56.7M shares	47.1M shares
Weighted-average shares outstanding, diluted	56.7M shares	47.1M shares

Total assets³⁴⁵⁶⁷⁸$476.2M in 2025+1330% since 2019

Total liabilities³⁴⁵⁶⁷⁸$16.6M in 2025+278% since 2019

Shareholders’ equity⁴⁵⁶⁷⁸$459.6M in 2025

Cash³⁴⁵⁶⁷⁸$98.9M in 2025+1904% since 2019

Every line of the balance sheet as filed: the last 4 fiscal years (annual) or 4 quarters (quarterly), latest first.⁸

Period ending	2025-12-31	2025-01-31	2024-12-31	2023-12-31
Cash and cash equivalents	$98.9M		$124.1M
Marketable securities	$363.7M		$189.3M
Restricted cash	$0		$54.0K
Prepaid expenses and other current assets	$12.3M		$4.6M
Total current assets	$474.9M		$318.1M
Property and equipment, net	$34.0K		$458.0K
Operating lease right-of-use assets	$383.0K	$700.0K	$0
Deferred offering costs	$217.0K		$0
Other long-term assets	$656.0K		$7.2M
Total assets	$476.2M		$325.8M
Accounts payable	$2.2M		$1.3M
Accrued expenses and other current liabilities	$14.4M		$14.6M
Total current liabilities	$16.6M		$15.9M
Total liabilities	$16.6M		$15.9M
Preferred stock, par value $0.001; authorized shares - 10,000,000; issued and outstanding shares - none	$0		$0
Common stock, par value $0.001; authorized shares - 100,000,000; issued and outstanding shares - 59,440,045 and 48,936,459 at December 31, 2025 and 2024, respectively	$59.0K		$49.0K
Additional paid-in capital	$806.4M		$553.2M
Accumulated other comprehensive income	$334.0K		$55.0K
Accumulated deficit	-$347.2M		-$243.5M
Total stockholders' equity	$459.6M		$309.8M	$245.9M
Total liabilities and stockholders' equity	$476.2M		$325.8M
Preferred stock, par value	$0.00		$0.00
Preferred stock, shares authorized	10.0M shares		10.0M shares
Preferred stock, shares issued	0 shares		0 shares
Preferred stock, shares outstanding	0 shares		0 shares
Common stock, par value	$0.00		$0.00
Common stock, shares authorized	100.0M shares		100.0M shares
Common stock, shares issued	59.4M shares		48.9M shares
Common stock, shares outstanding	59.4M shares		48.9M shares

Period ending	2025-12-31	2025-01-31	2024-12-31	2023-12-31
Cash and cash equivalents	$98.9M		$124.1M
Marketable securities	$363.7M		$189.3M
Restricted cash	$0		$54.0K
Prepaid expenses and other current assets	$12.3M		$4.6M
Total current assets	$474.9M		$318.1M
Property and equipment, net	$34.0K		$458.0K
Operating lease right-of-use assets	$383.0K	$700.0K	$0
Deferred offering costs	$217.0K		$0
Other long-term assets	$656.0K		$7.2M
Total assets	$476.2M		$325.8M
Accounts payable	$2.2M		$1.3M
Accrued expenses and other current liabilities	$14.4M		$14.6M
Total current liabilities	$16.6M		$15.9M
Total liabilities	$16.6M		$15.9M
Preferred stock, par value $0.001; authorized shares - 10,000,000; issued and outstanding shares - none	$0		$0
Common stock, par value $0.001; authorized shares - 100,000,000; issued and outstanding shares - 59,440,045 and 48,936,459 at December 31, 2025 and 2024, respectively	$59.0K		$49.0K
Additional paid-in capital	$806.4M		$553.2M
Accumulated other comprehensive income	$334.0K		$55.0K
Accumulated deficit	-$347.2M		-$243.5M
Total stockholders' equity	$459.6M		$309.8M	$245.9M
Total liabilities and stockholders' equity	$476.2M		$325.8M
Preferred stock, par value	$0.00		$0.00
Preferred stock, shares authorized	10.0M shares		10.0M shares
Preferred stock, shares issued	0 shares		0 shares
Preferred stock, shares outstanding	0 shares		0 shares
Common stock, par value	$0.00		$0.00
Common stock, shares authorized	100.0M shares		100.0M shares
Common stock, shares issued	59.4M shares		48.9M shares
Common stock, shares outstanding	59.4M shares		48.9M shares

Cash from operations³⁴⁵⁶⁷⁸-$70.3M in 2025+221% since 2019

Every line of the cash flow as filed: the last 2 fiscal years, latest first.⁸

Period ending	2025-12-31	2024-12-31
Net loss	-$103.7M	-$89.0M
Depreciation	$263.0K	$317.0K
Stock-based compensation	$34.0M	$20.2M
Non-cash lease expense	$353.0K	$320.0K
Amortization of premiums and discounts on marketable securities, net	-$227.0K	$424.0K
Change in fair value of contingent value right liability	$0	-$873.0K
Loss on disposal of property and equipment	$106.0K	$11.0K
Prepaid expenses, other current and long-term assets	-$1.1M	-$4.8M
Operating lease liabilities	-$337.0K	-$335.0K
Accounts payable	$817.0K	$810.0K
Accrued expenses and other liabilities	-$496.0K	-$248.0K
Net cash used in operating activities	-$70.3M	-$73.2M
Maturities of marketable securities	$272.9M	$313.9M
Purchases of marketable securities	-$446.8M	-$350.7M
Receipt of contingent value right milestone	$0	$10.0M
Payment of contingent value right milestone, net of permitted deductions	$0	-$9.1M
Purchases of property and equipment	-$158.0K	-$44.0K
Proceeds from sale of property and equipment	$213.0K	$0
Net cash used in investing activities	-$173.8M	-$36.0M
Proceeds from exercise of stock options	$2.3M	$3.6M
Proceeds from issuance of common stock under the Employee Stock Purchase Plan	$620.0K	$651.0K
Proceeds from issuance of common stock and pre-funded warrants in the Public Offering, net of issuance costs	$216.2M	$0
Proceeds from issuance of common stock and Pre-Funded Warrants in the Private Placement, net of issuance costs	$0	$89.7M
Proceeds from issuance of common stock under the Sales Agreement, net of issuance costs	$0	$39.2M
Payment of deferred offering costs	-$217.0K	$0
Net cash provided by financing activities	$218.9M	$133.2M
Net (decrease) increase in cash, cash equivalents and restricted cash	-$25.3M	$24.0M
Income taxes paid related to the contingent value right milestone	$0	$232.0K
Operating lease right-of-use assets obtained in exchange for operating lease liabilities	$736.0K	$0

Compare Enliven Therapeutics, Inc. with another company

Leadership

Who has led Enliven Therapeutics, Inc., and when. Pick a name to see everywhere that person has worked.

Chief executive

President

Chief financial officer

Benjamin Hohl2023–now

Chief operating officer

Anish Patel2023–now

2025

Chief executive officerRichard A. Fair Dec 12, 2025 to now¹¹
Chief executive officerSamuel Kintz Feb 27, 2023 to Dec 12, 2025¹²
Chief executive officerRahul D. Ballal Mar 11, 2020 to Feb 22, 2023¹³
PresidentRichard A. Fair Dec 12, 2025 to now¹¹
PresidentSamuel Kintz Feb 27, 2023 to Dec 12, 2025¹²
PresidentRahul D. Ballal Mar 11, 2020 to Mar 11, 2020¹³
Chief financial officerBenjamin Hohl Feb 27, 2023 to now¹⁴
Chief operating officerAnish Patel Feb 27, 2023 to now¹⁵

Board members and other officers (28)

Chief Medical OfficerHelen Louise Collins Feb 27, 2023 to now¹⁶
Chief Scientific OfficerJoseph P. Lyssikatos Feb 27, 2023 to now¹⁷
SVP, CMOKenneth Attie Jan 28, 2021 to Feb 1, 2022¹⁸
Chief Medical OfficerWillem Scheele Mar 11, 2020 to Mar 11, 2020¹⁹
Board memberJ. Scott Garland Jan 9, 2026 to now²⁰
Board memberRichard A. Fair Dec 12, 2025 to now¹¹
Board memberLori Anne Kunkel Apr 10, 2024 to now²¹
Board memberAndrew J. Schwab Feb 27, 2023 to Apr 6, 2023²²
Board memberAndrew John Phillips Feb 27, 2023 to Feb 10, 2025²³
Board memberHelen Louise Collins Feb 27, 2023 to Feb 27, 2023²⁴
Board memberJake Bauer Feb 27, 2023 to now²⁵
Board memberJoseph P. Lyssikatos Feb 27, 2023 to May 31, 2024¹⁷
Board memberMika K. Derynck Feb 27, 2023 to now²⁶
Board memberRichard A. Heyman Feb 27, 2023 to now²⁷
Board memberRishi Gupta Feb 27, 2023 to now²⁸
Board memberSamuel Kintz Feb 27, 2023 to now¹²
Board memberLaura A. Williams Jun 30, 2021 to Jun 3, 2022²⁹
Board memberAnthony A. Florence Jr. Dec 29, 2021 to Dec 29, 2021³⁰
Board memberBarbara Dalton Mar 11, 2020 to Jun 3, 2022³¹
Board memberCarl Goldfischer Mar 11, 2020 to Jun 3, 2022³²
Board memberDavid M. Mott Mar 11, 2020 to Jun 3, 2022³³
Board memberDavid P. Bonita Mar 11, 2020 to Jun 3, 2022³⁴
Board memberJames G. McArthur Mar 11, 2020 to Mar 16, 2020³⁵
Board memberMark Chin Mar 11, 2020 to Jun 3, 2022³⁶
Board memberMette Kirstine Agger Mar 11, 2020 to Mar 16, 2020³⁷
Board memberRahul D. Ballal Mar 11, 2020 to now¹³
Board memberSara M. Nayeem Mar 11, 2020 to Jun 30, 2021³⁸
Board memberEdward R. Conner Apr 23, 2020 to Jun 3, 2022³⁹

Former names

IMARA Inc.Apr 21, 2016 to Feb 23, 2023²

Timeline

Dec 12, 2025New chief executive Richard A. Fair becomes CEO¹¹
Feb 27, 2023New chief executive Samuel Kintz becomes CEO¹²
Mar 11, 2020New chief executive Rahul D. Ballal becomes CEO¹³

Filings

663 filings to the SEC since October 2021: 5 annual reports, 15 quarterly reports, 47 major events, 314 insider forms, 63 large holders, 1 private raises, 218 other. The latest 20:

Oct 14, 20268-K EDGAR
Oct 5, 20264 EDGAR
Oct 1, 2026144 EDGAR
Sep 21, 20264 EDGAR
Sep 21, 20264 EDGAR
Sep 17, 2026144 EDGAR
Sep 4, 2026144 EDGAR
Aug 19, 20264 EDGAR
Aug 19, 20264 EDGAR
Aug 6, 20264 EDGAR
Aug 6, 2026SCHEDULE 13G/A EDGAR
Aug 5, 202610-Q EDGAR
Aug 5, 20268-K EDGAR
Aug 4, 2026144 EDGAR
Jul 21, 20264 EDGAR
Jul 21, 20264 EDGAR
Jul 17, 2026144 EDGAR
Jul 8, 20264 EDGAR
Jun 24, 20264 EDGAR
Jun 24, 2026SCHEDULE 13D/A EDGAR

The 663 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last three years, summarized. The full record is on SEC EDGAR.

Insider trades and holders

Large holders

Investors who own more than 5% must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively. 63 such filings since October 2021, the latest 10:

From Forms 4 and Schedules 13D and 13G filed with the SEC.

Money raised

Private offerings the company reported to the SEC on Form D.

Mar 21, 2024Raised $90 million in a private offering of equity Form D: 20 investors so far Form D

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 100. Change is in shares since the quarter before.

Fund	Shares	Value	Share of the fund	Change
Fmr LLC	10,025,017	$508.8M	0.0%	+3,195,771
Orbimed Advisors LLC	6,776,632	$343.9M	6.5%	−1,182,906
Polar Capital Holdings Plc	6,430,636	$326.4M	0.9%	+1,364,703
BlackRock, Inc.	4,359,704	$221.3M	0.0%	+674,997
Vestal Point Capital, LP	4,000,000	$203.0M	4.7%	+750,000
Commodore Capital LP	3,275,000	$166.2M	9.9%	No change
Vanguard Capital Management LLC	2,569,002	$130.4M	0.0%	+400,840
Citadel Advisors LLC	2,068,992	$105.0M	0.1%	+325,077
Fairmount Funds Management LLC	1,855,644	$94.2M	6.2%	No change
Siren, L.L.C.	1,774,411	$90.1M	1.8%	+1,028,185
Bellevue Group AG	1,490,000	$75.6M	1.6%	−830,867
Geode Capital Management, LLC	1,407,202	$71.4M	0.0%	+340,782
First Light Asset Management, LLC	1,360,750	$69.1M	4.2%	+1,158,883
State Street Corp	1,213,616	$61.6M	0.0%	+122,510
Pictet Asset Management Holding SA	1,161,784	$59.0M	0.1%	+232,240
Adage Capital Partners Gp, L.l.c.	1,083,313	$55.0M	0.1%	New
Novo Holdings A/s	1,000,000	$50.8M	2.9%	−280,000
First Turn Management, LLC	954,360	$48.4M	5.2%	+330,521
Samlyn Capital, LLC	912,637	$46.3M	0.8%	New
Baker Bros. Advisors LP	905,191	$45.9M	0.2%	No change
Candriam S.C.A.	905,674	$45.9M	0.2%	+311,595
Tri Locum Partners LP	866,716	$44.0M	5.4%	New
Alliancebernstein L.P.	896,161	$35.1M	0.0%	+124,276
Dimensional Fund Advisors LP	671,412	$34.1M	0.0%	−10,303
Assenagon Asset Management S.A.	613,148	$31.1M	0.0%	New

13F reports cover disclosed long positions in U.S. stocks only.

Sources

The numbers on this page point here. Each one links to the record it came from.

1
SEC EDGAREnliven Therapeutics, Inc. filings on SEC EDGAR
2
SEC EDGAREnliven Therapeutics, Inc. filings on SEC EDGAR
3
SEC EDGAREnliven Therapeutics, Inc. 10-K for fiscal 2019
4
SEC EDGAREnliven Therapeutics, Inc. 10-K for fiscal 2020
5
SEC EDGAREnliven Therapeutics, Inc. 10-K for fiscal 2021
6
SEC EDGAREnliven Therapeutics, Inc. 10-K for fiscal 2022
7
SEC EDGAREnliven Therapeutics, Inc. 10-K for fiscal 2023
8
SEC EDGAREnliven Therapeutics, Inc. 10-K for fiscal 2024
9
SEC EDGAREnliven Therapeutics, Inc. 10-Q for fiscal 2026
10
SEC EDGAREnliven Therapeutics, Inc. 10-Q for fiscal 2026
11
SEC EDGARRichard A. Fair, Chief executive officer
12
SEC EDGARSamuel Kintz, Chief executive officer
13
SEC EDGARRahul D. Ballal, Chief executive officer
14
SEC EDGARBenjamin Hohl, Chief financial officer
15
SEC EDGARAnish Patel, Chief operating officer
16
SEC EDGARHelen Louise Collins, Chief Medical Officer
17
SEC EDGARJoseph P. Lyssikatos, Chief Scientific Officer
18
SEC EDGARKenneth Attie, SVP, CMO
19
SEC EDGARWillem Scheele, Chief Medical Officer
20
SEC EDGARJ. Scott Garland, Board member
21
SEC EDGARLori Anne Kunkel, Board member
22
SEC EDGARAndrew J. Schwab, Board member
23
SEC EDGARAndrew John Phillips, Board member
24
SEC EDGARHelen Louise Collins, Board member
25
SEC EDGARJake Bauer, Board member
26
SEC EDGARMika K. Derynck, Board member
27
SEC EDGARRichard A. Heyman, Board member
28
SEC EDGARRishi Gupta, Board member
29
SEC EDGARLaura A. Williams, Board member
30
SEC EDGARAnthony A. Florence Jr., Board member
31
SEC EDGARBarbara Dalton, Board member
32
SEC EDGARCarl Goldfischer, Board member
33
SEC EDGARDavid M. Mott, Board member
34
SEC EDGARDavid P. Bonita, Board member
35
SEC EDGARJames G. McArthur, Board member
36
SEC EDGARMark Chin, Board member
37
SEC EDGARMette Kirstine Agger, Board member
38
SEC EDGARSara M. Nayeem, Board member
39
SEC EDGAREdward R. Conner, Board member